AbbVie's Stock Pulls Back After Reaching Record Highs, Offering Potential Buying Opportunity
AbbVie's stock has declined by about 13% from its record high of $238.71 set on October 1, 2025, due to macroeconomic headwinds and concerns over its newer drugs. Despite the pullback, the stock remains reasonably valued and offers an attractive dividend yield of 4.02%. The company's long-term growth potential is still seen as strong, especially with its immunology drugs Skyrizi and Rinvoq.
Tickers: $ABBV
Topics: competitive pressures dividend yield market sentiment regulatory issues stock price movement